Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide before bariatric surgery for diabetes remission in obese type 2 diabetes mellitus
ChiCTR2100053486Phase 4Recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: Glycated hemoglobin (HbA1c). Started Dec 2021; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on ChiCTR2100053486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053486.